RIGL

Rigel Pharmaceuticals Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 9/10
  • Momentum↑ 6/10
Rigel Pharmaceuticals sales and earnings growth
RIGL Growth
Great
  • Revenue Y/Y↑ 79.13%
  • EPS Y/Y↑ 2652.17%
  • FCF Y/Y↑ 550.01%
Rigel Pharmaceuticals gross and profit margin trends
RIGL Profitability
Great
  • Gross margin ↑ 93.10%
  • EPS margin↑ 40.20%
  • ROIC↑ 118.40%
Rigel Pharmaceuticals net debt vs free cash flow
RIGL Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↓ 0.2
  • Interest coverage↑ 16.1

Rigel Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗